Disclaimer
Het alfapump®-systeem is momenteel niet goedgekeurd in de Verenigde Staten of Canada. In de Verenigde Staten en Canada wordt het alfapump®-systeem momenteel klinisch onderzocht (POSEIDON-studie) en wordt het bestudeerd bij volwassen patiënten met refractaire of terugkerende ascites als gevolg van levercirrose. DSR®-therapie is nog in ontwikkeling en er dient te worden opgemerkt dat eventuele verklaringen met betrekking tot veiligheid en efficiëntie voortkomen uit lopende preklinische en klinische onderzoeken die nog moeten worden afgerond. Er is geen verband tussen de DSR®-therapie en de lopende onderzoeken met het alfapump®-systeem in Europa, de Verenigde Staten of Canada.
This website (hereinafter the “Website“) is provided by SEQUANA MEDICAL (hereinafter “us” or “we”).
This website (hereinafter the “Website“) is provided by SEQUANA MEDICAL (hereinafter “us” or “we”).
Purpose and content | Lifespan |
---|---|
Website analysis with Google Analytics: These cookies assign a randomly generated ID to your device, enabling us to recognize your device upon your next access. For details on website analysis, please see the respective chapter below. | 6 months |
Analysis of webcast with Multimedia Center from Nasdaq: These Cookies enable us to analyze your use of the webcast by assigning a unique and randomly generated ID to your device that lets us recognize if you have used the Multimedia Center player once before. | 12 months |
Google Analytics
On our Website, we use Google Analytics, a web analysis service of Google Inc., 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States (“Google”).
Google will analyze your use of our Website on our behalf. To this purpose, we use, among others, the cookies described in more detail in the above table. The information collected by Google in connection with your use of our Website (e.g. the referring URL, our web pages visited by you, your browser type, your language settings, your operating system, your screen resolution) will be transmitted to a server of Google in the US, where it will be stored and analyzed. The respective results will then be made available to us in anonymized form. Your usage data will not be connected to your full IP address during this process. We have activated on our Website the IP anonymizing function offered by Google, which will delete the last eight digits (type IPv4) or the last 80 bits (type IPv6) of your IP address. Moreover, Google is certified under the EU-US Privacy Shield, which ensures that an adequate level of data protection is maintained with respect to the processing of data by Google in the US.
You may revoke your consent to the use of web analysis at any time, either by downloading and installing the provided Google Browser Plugin or by administrating your consents in the above table, in which case an opt-out cookie will be placed. Both options will prevent the application of web analysis only as long as you use the browser on which you installed the plugin and do not delete the opt-out cookie.
Further information on Google Analytics is available in the Google Analytics Terms of Use, the Privacy and Data Protection Guidelines of Google Analytics and in the Google Privacy Policy.
On our website, we use the external analytics service Multimedia Center of our webcast provider Webcasts NASDAQ OMX Corporate Solutions International Limited, (“Corporate Solutions”) a NASDAQ, Inc. company, Nasdaq Offices, Woolgate Exchange, 25 Basinghall Street, London EC2V 5HA, Great Britain („Nasdaq“).
Nasdaq will analyze your use of our webcast on our behalf.
To this purpose, we use, among others, the cookies described in more detail in the above table. The information collected by Nasdaq in connection with your use of our webcast (e.g. the referring URL, our webpages visited by you, your browser type, your language settings, your operating system, your screen resolution, date, duration of your viewing, part of the webcast you viewed) will be transmitted to a server of Nasdaq in Germany, where it will be stored and analyzed. The respective results will then be made available to us in anonymized form. Your usage data will not be connected to your full IP address during this process.
You may revoke your consent to the use of web analysis for webcasts at any time by administrating your consents in the above table, in which case an opt-out cookie will be placed.
Further information on Nasdaq is available in the Nasdaq privacy statement.
You can contact us directly via the contact forms available on our Website. In particular, you may provide us with the following information:
We collect, process and use the information provided by you via the contact forms exclusively for the processing of your specific request.
This Website is not intended or designed for communications on issues regarding the safeness or quality of products. If you wish to make a quality complaint, please contact your health care professional (e.g., a physician or pharmacist) or your local health authority.
For the processing of your data, we will to some extent use specialized service contractors. Such service contractors are carefully selected and regularly monitored by us. Based on respective data processor agreements, they will only process personal data upon our instruction and strictly in accordance with our directives.
Your data will in part also be processed in countries outside the European Union (“EU”) or the European Economic Area (“EEA”), more specifically Switzerland. We will ensure that a sufficient level of protection is provided for your data.
The following rights are in general available to you according to applicable data privacy laws:
If you wish to exercise your rights, please address your request to the contact form or to our company data protection office indicated below.
For any questions you may have concerning data privacy, please contact our company data protection manager at the following address:
Sequana Medical NV, Kortrijksesteenweg 1112, 9051 Sint-Denijs-Westrem, Belgium
We may update our Privacy Statement from time to time. Updates of our Privacy Statement will be published on our Website. Any amendments become effective upon publication on our Website. We, therefore, recommend that you regularly visit the site to keep yourself informed on possible updates.
Last updated: October 29th, 2018